top of page
OUR PIPELINE

Publications & Presentations

ATS Poster 2025.png

ATS 2025

In vitro characterization of solrikitug, a differentiated anti-TSLP antibody, provides distinct epitope binding profile and superior potency compared to tezepelumab

mAB
We are actively expanding our immunology and inflammation pipeline, with a laser focus on therapeutics for indications with limited or no available treatments.
mAB
bottom of page